Navigation Links
Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
Date:7/9/2012

CAMBRIDGE, Mass., July 10, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the agency has placed a clinical hold on clinical trials evaluating the safety and efficacy of IB1001, an intravenous recombinant factor IX (rFIX) being investigated for the treatment and prevention of bleeding episodes in people with hemophilia B. 

The clinical hold impacts two ongoing IB1001 clinical trials – a phase 3 study evaluating the safety and efficacy of IB1001 to treat and prevent bleeding episodes in adults with hemophilia B, and a phase 3/3b study evaluating the safety and efficacy of IB1001 to treat and prevent bleeding episodes in previously treated pediatric subjects with hemophilia B. The adult study has completed its primary analysis period.

Inspiration recently reported to the FDA that, during the course of routine laboratory evaluations conducted as part of an ongoing phase 3 clinical trial, the Company discovered that a higher proportion of individuals treated with IB1001 have developed antibodies to proteins from the Chinese hamster ovary, or CHO, host cells used to manufacture the therapy than was expected based on earlier study data. Inspiration has notified clinical sites in the U.S. to hold treatment of patients with IB1001. Inspiration is also sharing the FDA directive with regulators in countries outside of the U.S. where the studies are being conducted.

Small amounts of host cell protein are expected and documented in recombinant therapeutic products of all types. Nevertheless, the higher than expected rate of anti-CHO antibody development in people treated with IB1001 has led Inspiration to initiate a thorough investigation.

A total of 86 people with hemophilia B have received IB1001 in clinical studies and, to date, no adverse events related to the development of antibodies to CHO protein ha
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
2. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEWPORT BEACH, Calif. , Sept. 30, 2014 ... prestigious accreditation of the American Association of Tissue ... Russell Cook , Chief Executive Officer. ... on-site inspection by a specially trained AATB inspector.  ... and administrative performance within the facility meets or ...
(Date:9/30/2014)... -- Georgia-Pacific Professional is a leading provider of hygienic ... range of away from home applications. Building on ... including hospitals, long-term care facilities, surgical centers and ... products and solutions to the dental community. ... control in the dental office," said Sean ...
(Date:9/30/2014)... , Sept. 30, 2014 Passport Health, ... America , has launched FluFree.com, a website designed ... vaccinations. For 20 years, Passport Health has ... the flu. The launch of FluFree.com is designed to ... and the number of people who actually chose to ...
Breaking Medicine Technology:Biostructures, LLC Earns AATB Accreditation 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3
... CAMBRIDGE, Mass. Dec. 10 The US Army, through the ... Technologies a contract to develop a robotic approach to airway ... clearing a patient,s airway and inserting a tube to maintain ... intubation, is critical as the loss of proper air circulation ...
... , TITUSVILLE, N.J., Dec. 10 Treatment with once-monthly ... CONSTA®, according to new data from a comparative study of ... clinical trial were released this week. , An estimated one ... brain disorder that impairs a person,s ability to think clearly, ...
Cached Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10
(Date:9/30/2014)... unusual character from a "Seinfeld" episode or a John ... called SCID, short for severe combined immunodeficiency, forces patients ... their bodies, natural defenses are too weak to fight ... new births each year worldwide, SCID is a cousin ... immunodeficiency virus HIV/AIDS. , Now, using a mouse ...
(Date:9/30/2014)... Researchers report that some stickleback fish fathers can have ... most attentive fish dads cause their offspring to behave ... predators. These behavioral changes are accompanied by changes in ... appear in the Proceedings of the Royal ... of evidence that moms are very important for their ...
(Date:9/30/2014)... a very valuable procedure by which to screen ... seems that healthy Americans who do undergo this ... before they actually should. Gina Kruse of ... advise that endoscopists stick to the national guidelines ... Journal of General Internal Medicine , published by ...
(Date:9/30/2014)... Carolina (PRWEB) September 30, 2014 ... and IT Infrastructure analytics across data center, cloud ... has achieved an important milestone of helping more ... plan for important projects such as IT infrastructure ... , The strong customer engagement rates and ...
(Date:9/30/2014)... September 30, 2014 A market research ... intelligence agency states that the global medical imaging reagents ... 18.5 billion by the end of 2019. The worldwide ... 10.3 billion in 2012, will report a compounded annual ... 18.5 billion worth market by 2019. , Browse the ...
Breaking Medicine News(10 mins):Health News:Virginia Tech researchers discover potential biomarker to detect 'bubble boy' disorder 2Health News:Virginia Tech researchers discover potential biomarker to detect 'bubble boy' disorder 3Health News:In stickleback fish, dads influence offspring behavior and gene expression 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 3Health News:Americans undergo colonoscopies too often, study finds 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 2Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 3
... ... provide alternative natural relief prior to considering drugs. , ... St. Louis, MO (PRWEB) December 17, 2009 -- ... and flaking associated with severe skin conditions . Developed by Astrel Genome ...
... ... measures and outcomes reporting to monitor the impact of expected health improvements as it ... the contract. , ... Jacksonville, FL (PRWEB) December 17, 2009 -- HealthScreen Disease Management, an independent ...
... ... tub company helps raise money for kids battling severe illness and acute injury ... Salt Lake City, ... donation of a Bullfrog Spa to aid in fund raising efforts for Primary Children’s ...
... AUSTIN, Texas, Dec. 16 Austin,s Custom Tops , a ... Gray and Hill Country Home Health, a slider-eating throwdown at the ... up to cheer on the two brave contestants who ate their ... The Austin Children,s Shelter. , What started as a casual ...
... , CHEVY CHASE, Md., Dec. 16 ... capital firm, today announced that one of its portfolio ... to be acquired by Ethicon, Inc., a Johnson & ... million (net of estimated cash on hand at time ...
... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... today announced that Paul D. Mintz, M.D. has been appointed ... 1, 2010. , Dr. Mintz has been involved in ... He is a tenured Professor of Pathology and Medicine at ...
Cached Medicine News:Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2Health News:Bullfrog Spas Helps Critically Ill Children 2Health News:Bullfrog Spas Helps Critically Ill Children 3Health News:Bullfrog Spas Helps Critically Ill Children 4Health News:Austin-Based Business Co-Sponsors Gastric Feat for Charity 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Immucor Appoints New Board Director 2
Cannulated Interference Screws...
... Endoscopy Components, LLC offers ... Equipment "Made in Germany". ... manufactured according to ISO ... most excellent design elements ...
... moisturizing mist for the eyes developed with ... from Oregon Health Sciences University's Casey Eye ... (2000) and dry eye patients showed, on ... volume of the eyes' tear film without ...
... array with 275 channels gives ... just 2.2 cm. This ... when using advanced analysis techniques, ... (SAM) or minimum norm methods. ...
Medicine Products: